{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:24:59Z","timestamp":1787930699399,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/ftd.0b013e31828d50ef","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T22:21:29Z","timestamp":1373667689000},"page":"552-556","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir\/Ritonavir 800\/100 mg Once Daily in HIV-1\u2013Infected Patients"],"prefix":"10.1097","volume":"35","author":[{"given":"Maria","family":"Mart\u00ednez-Rebollar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Lonc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-17-20210129","doi-asserted-by":"crossref","first-page":"M47","DOI":"10.1177\/135965350501002S05","article-title":"Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria.","volume":"10","author":"Moyle","year":"2005","journal-title":"Antivir Ther"},{"key":"R2-17-20210129","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"D:A:D Study Group, Sabin CA, Worm SW, et al.. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"R3-17-20210129","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","article-title":". Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.","volume":"40","author":"Gallant","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R4-17-20210129","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":". TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-17-20210129","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":". Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R6-17-20210129","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1310\/hct0906-418","article-title":"Pharmacokinetics, efficacy, and safety of darunavirritonavir 800100 mg once-daily in treatment-naive and -experienced patients.","volume":"9","author":"Boffito","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R7-17-20210129","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":". Once-daily darunavirritonavir vs. lopinavirritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"R8-17-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801300101","article-title":"Darunavir: pharmacokinetics and drug interactions.","volume":"13","author":"Back","year":"2008","journal-title":"Antivir Ther"},{"key":"R9-17-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003088-200746090-00002","article-title":"Clinical pharmacokinetics of darunavir.","volume":"46","author":"Rittweger","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R10-17-20210129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":". Raltegravir with optimized background therapy for resistant HIV-1 infection.","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"R11-17-20210129","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":". Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multi-centre, double-blind randomised controlled trial.","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R12-17-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":". Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-17-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":". Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-17-20210129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.clpt.6100281","article-title":". Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.","volume":"83","author":"Iwamoto","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R15-17-20210129","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":". Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R19-17-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3851\/IMP1517","article-title":". The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.","volume":"15","author":"Garvey","year":"2010","journal-title":"Antivir Ther"},{"key":"R20-17-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2010.11.009","article-title":". Darunavirritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.","volume":"63","author":"Fabbiani","year":"2011","journal-title":"Pharmacol Res"},{"key":"R21-17-20210129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.phrs.2011.09.006","article-title":". Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.","volume":"65","author":"Cattaneo","year":"2012","journal-title":"Pharmacol Res"},{"key":"R22-17-20210129","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":". Efficacy of a nucleoside-sparing regimen of darunavirritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).","volume":"25","author":"Taiwo","year":"2011","journal-title":"AIDS"},{"key":"R23-17-20210129","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2125.2007.02957.x","article-title":". Pharmacokinetic interaction between TMC114ritonavir and tenofovir disoproxil fumarate in healthy volunteers.","volume":"64","author":"Hoetelmans","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R24-17-20210129","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1177\/0091270010387428","article-title":". Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.","volume":"51","author":"Brainard","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R25-17-20210129","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/QAI.0b013e3182364c67","article-title":". Plasma and intracellular pharmacokinetics of darunavirritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.","volume":"58","author":"Jackson","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-17-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkr498","article-title":". Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.","volume":"67","author":"Cattaneo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R27-17-20210129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/aid.2010.0370","article-title":". Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.","volume":"28","author":"Garrido","year":"2012","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31828d50ef","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:25:18Z","timestamp":1688358318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201308000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31828d50ef","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}